Literature DB >> 24357284

Breakthrough of the year 2013. Cancer immunotherapy.

Jennifer Couzin-Frankel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24357284     DOI： 10.1126/science.342.6165.1432

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  681 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

Review 2.  Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors.

Authors:  Denis L Jardim; Débora de Melo Gagliato; Francis J Giles; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-12-06       Impact factor: 12.531

Review 3.  Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumour microenvironment.

Authors:  Yunlu Dai; Can Xu; Xiaolian Sun; Xiaoyuan Chen
Journal:  Chem Soc Rev       Date:  2017-05-18       Impact factor: 54.564

Review 4.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

5.  Nrf2 Deficiency Promotes Melanoma Growth and Lung Metastasis.

Authors:  Hong Zhu; Zhenquan Jia; Michael A Trush; Y Robert Li
Journal:  React Oxyg Species (Apex)       Date:  2016-05-30

Review 6.  Medulloblastoma development: tumor biology informs treatment decisions.

Authors:  Vidya Gopalakrishnan; Rong-Hua Tao; Tara Dobson; William Brugmann; Soumen Khatua
Journal:  CNS Oncol       Date:  2015

7.  EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity.

Authors:  Michael Peled; Matthew A Dragovich; Kieran Adam; Marianne Strazza; Anna S Tocheva; Irving E Vega; Adam Mor
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

Review 8.  Revisiting the hallmarks of cancer.

Authors:  Yousef Ahmed Fouad; Carmen Aanei
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

9.  Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.

Authors:  Cynthia L Gay; Ronald J Bosch; Justin Ritz; Jason M Hataye; Evgenia Aga; Randall L Tressler; Stephen W Mason; Carey K Hwang; Dennis M Grasela; Neelanjana Ray; Josh C Cyktor; John M Coffin; Edward P Acosta; Richard A Koup; John W Mellors; Joseph J Eron
Journal:  J Infect Dis       Date:  2017-06-01       Impact factor: 5.226

10.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.